152 related articles for article (PubMed ID: 34109562)
1. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study.
Custodio A; Jimenez-Fonseca P; Carmona-Bayonas A; Gomez MJ; Del Olmo-García MI; Lorenzo I; Díaz JÁ; Canal N; De la Cruz G; Villabona C
Clin Transl Oncol; 2021 Oct; 23(10):2046-2056. PubMed ID: 34109562
[TBL] [Abstract][Full Text] [Related]
2. Real-world treatment patterns, resource use and costs of treating uncontrolled carcinoid syndrome and carcinoid heart disease: a retrospective Swedish study.
Lesén E; Björstad Å; Björholt I; Marlow T; Bollano E; Feuilly M; Marteau F; Welin S; Elf AK; Johanson V
Scand J Gastroenterol; 2018 Dec; 53(12):1509-1518. PubMed ID: 30449217
[TBL] [Abstract][Full Text] [Related]
3. Direct costs of carcinoid syndrome diarrhea among adults in the United States.
Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
World J Gastroenterol; 2019 Dec; 25(47):6857-6865. PubMed ID: 31885426
[TBL] [Abstract][Full Text] [Related]
4. Healthcare and economic impact of diarrhea in patients with carcinoid syndrome.
Broder MS; Chang E; Romanus D; Cherepanov D; Neary MP
World J Gastroenterol; 2016 Feb; 22(6):2118-25. PubMed ID: 26877616
[TBL] [Abstract][Full Text] [Related]
5. Burden of Carcinoid Heart Disease in Patients With Carcinoid Syndrome Initiating Somatostatin Analogues.
Joish VN; Perez-Olle R; Lapuerta P; Dharba S; Zacks J
Clin Ther; 2019 Sep; 41(9):1716-1723.e2. PubMed ID: 31326125
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs Between Octreotide and Lanreotide Among Patients With Neuroendocrine Tumors.
Huynh L; Cai B; Cheng M; Lax A; Lejeune D; Duh MS; Kim MK
Pancreas; 2019 Oct; 48(9):1126-1135. PubMed ID: 31593022
[TBL] [Abstract][Full Text] [Related]
7. The impact of poor asthma control among asthma patients treated with inhaled corticosteroids plus long-acting β
Pavord ID; Mathieson N; Scowcroft A; Pedersini R; Isherwood G; Price D
NPJ Prim Care Respir Med; 2017 Mar; 27(1):17. PubMed ID: 28270657
[TBL] [Abstract][Full Text] [Related]
8. Patient-Reported Lupus Flare Symptoms Are Associated with Worsened Patient Outcomes and Increased Economic Burden.
Katz P; Nelson WW; Daly RP; Topf L; Connolly-Strong E; Reed ML
J Manag Care Spec Pharm; 2020 Mar; 26(3):275-283. PubMed ID: 32105178
[TBL] [Abstract][Full Text] [Related]
9. Health care resource use and costs among patients with carcinoid syndrome in France: Analysis of the National Health Insurance Database.
Perrier M; Mouawad C; Gueguen D; Thomé B; Lapeyre-Mestre M; Walter T
Clin Res Hepatol Gastroenterol; 2023 Aug; 47(7):102177. PubMed ID: 37453678
[TBL] [Abstract][Full Text] [Related]
10. Work productivity burden and indirect costs associated with carcinoid syndrome diarrhea.
Dasari A; Joish VN; Perez-Olle R; Dharba S; Balaji K; Halperin DM
Expert Rev Pharmacoecon Outcomes Res; 2020 Oct; 20(5):507-511. PubMed ID: 31448649
[No Abstract] [Full Text] [Related]
11. Patient characteristics and hospitalisation costs of spinal muscular atrophy in Spain: a retrospective multicentre database analysis.
Darbà J; Marsà A
BMJ Open; 2019 Nov; 9(11):e031271. PubMed ID: 31753879
[TBL] [Abstract][Full Text] [Related]
12. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
[TBL] [Abstract][Full Text] [Related]
13. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.
Burton T; Lapuerta P
Future Oncol; 2018 Oct; 14(23):2361-2370. PubMed ID: 30095284
[TBL] [Abstract][Full Text] [Related]
14. Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.
Manjunath R; Paradis PE; Parisé H; Lafeuille MH; Bowers B; Duh MS; Lefebvre P; Faught E
Neurology; 2012 Oct; 79(18):1908-16. PubMed ID: 23077014
[TBL] [Abstract][Full Text] [Related]
15. Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma.
Lee LK; Ramakrishnan K; Safioti G; Ariely R; Schatz M
BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32193226
[TBL] [Abstract][Full Text] [Related]
16. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.
Shen C; Chu Y; Halperin DM; Dasari A; Zhou S; Xu Y; Yao JC; Shih YT
Oncologist; 2017 Dec; 22(12):1451-1462. PubMed ID: 28642335
[TBL] [Abstract][Full Text] [Related]
17. Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources.
Darbà J; Marsà A
BMC Cancer; 2019 Dec; 19(1):1226. PubMed ID: 31842791
[TBL] [Abstract][Full Text] [Related]
18. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
[TBL] [Abstract][Full Text] [Related]
19. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Fust K; Maschio M; Kohli M; Singh S; Pritchard DM; Marteau F; Myrenfors P; Feuilly M
Pharmacoeconomics; 2020 Jun; 38(6):607-618. PubMed ID: 32157590
[TBL] [Abstract][Full Text] [Related]
20. Direct non-medical and indirect costs of diabetes and its associated complications in Vietnam: an estimation using national health insurance claims from a cross-sectional survey.
Kieu TTM; Trinh HN; Pham HTK; Nguyen TB; Ng JYS
BMJ Open; 2020 Mar; 10(3):e032303. PubMed ID: 32132135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
